Seres therapeutics announces initiation of phase 1b trial of ser-301 for the treatment of ulcerative colitis

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) today announced that it has dosed the first patient in its phase 1b trial evaluating ser-301 for the treatment of active mild-to-moderate ulcerative colitis (uc). ser-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis and induce clinical remission in patients suffering from active uc. ser-301 is designed to modify the gast
MCRB Ratings Summary
MCRB Quant Ranking